{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T13:03:59Z","timestamp":1779109439967,"version":"3.51.4"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T00:00:00Z","timestamp":1592352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T00:00:00Z","timestamp":1592352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s40268-020-00311-6","type":"journal-article","created":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T13:03:46Z","timestamp":1592399026000},"page":"171-187","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Cutaneous Adverse Events in Newly Approved FDA Non-cancer Drugs: A Systematic Review"],"prefix":"10.1007","volume":"20","author":[{"given":"Paul C.","family":"Macklis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brittany","family":"Dulmage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brady","family":"Evans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Misha","family":"Rosenbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johann E.","family":"Gudjonsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8079-0011","authenticated-orcid":false,"given":"Benjamin H.","family":"Kaffenberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,17]]},"reference":[{"issue":"1","key":"311_CR1","doi-asserted-by":"publisher","first-page":"41","DOI":"10.4103\/ijd.IJD_65_17","volume":"63","author":"SG Biswal","year":"2018","unstructured":"Biswal SG, Mehta RD. Cutaneous adverse reactions of chemotherapy in cancer patients: a clinicoepidemiological study. Indian J Dermatol. 2018;63(1):41\u20136. https:\/\/doi.org\/10.4103\/ijd.IJD_65_17.","journal-title":"Indian J Dermatol"},{"issue":"2018","key":"311_CR2","first-page":"5376476","volume":"17","author":"CY Ng","year":"2018","unstructured":"Ng CY, Chen C-B, Wu M-Y, et al. Anticancer drugs induced severe adverse cutaneous drug reactions: an updated review on the risks associated with anticancer targeted therapy or immunotherapies. J Immunol Res. 2018;17(2018):5376476.","journal-title":"J Immunol Res"},{"issue":"2","key":"311_CR3","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1097\/CAD.0000000000000032","volume":"25","author":"AC Rosen","year":"2014","unstructured":"Rosen AC, Balagula Y, Raisch DW, et al. Life-threatening dermatologic adverse events in oncology. Anticancer Drugs. 2014;25(2):225\u201334. https:\/\/doi.org\/10.1097\/CAD.0000000000000032.","journal-title":"Anticancer Drugs"},{"key":"311_CR4","unstructured":"EMA. Zenapax [prescribing information]. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zenapax-epar-product-information_en.pdf. Accessed 12 May 2020."},{"key":"311_CR5","unstructured":"MPR. Roche discontinues Zenapax injection. Published 22 December, 2009. https:\/\/www.empr.com\/home\/news\/roche-discontinues-zenapax-injection\/. Accessed 12 May 2020."},{"key":"311_CR6","unstructured":"GOV.UK. Daclizumab beta (Zinbryta\u25bc): risk of immune-mediated encephalitis: some cases several months after stopping treatment. https:\/\/www.gov.uk\/drug-safety-update\/daclizumab-beta-zinbryta-risk-of-immune-mediated-encephalitis-some-cases-several-months-after-stopping-treatment. Accessed 12 May 2020."},{"issue":"1","key":"311_CR7","doi-asserted-by":"publisher","first-page":"84","DOI":"10.4049\/jimmunol.1402140","volume":"194","author":"DJ Huss","year":"2015","unstructured":"Huss DJ, Mehta DS, Sharma A, et al. In vivo maintenance of human regulatory T cells during CD25 blockade. J Immunol. 2015;194(1):84\u201392. https:\/\/doi.org\/10.4049\/jimmunol.1402140.","journal-title":"J Immunol"},{"key":"311_CR8","unstructured":"US FDA. Zinbryta (daclizumab) injection, for subcutaneous use [prescribing information]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761029s007lbl.pdf. Accessed 22 Dec 2019."},{"key":"311_CR9","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.msard.2019.08.008","volume":"35","author":"A Lockhart","year":"2019","unstructured":"Lockhart A, Kirby B, McGuigan C. Rash developing after cessation of daclizumab for relapsing remitting MS; a case series. Mult Scler Relat Disord. 2019;35:239\u201340. https:\/\/doi.org\/10.1016\/j.msard.2019.08.008.","journal-title":"Mult Scler Relat Disord"},{"key":"311_CR10","unstructured":"US FDA. Dupixent (dupilumab) injection. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761055lbl.pdf. Accessed 22 Jan 2020."},{"key":"311_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18730","author":"LEM de Wijs","year":"2019","unstructured":"de Wijs LEM, Nguyen NT, Kunkeler ACM, Nijsten T, Damman J, Hijnen DJ. Clinical and histopathological characterization of paradoxical head and neck erythema in patients with atopic dermatitis treated with dupilumab: a case series. Br J Dermatol. 2019. https:\/\/doi.org\/10.1111\/bjd.18730.","journal-title":"Br J Dermatol"},{"issue":"1","key":"311_CR12","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.jaad.2019.06.026","volume":"82","author":"RA Waldman","year":"2020","unstructured":"Waldman RA, DeWane ME, Sloan B, Grant-Kels JM. Characterizing dupilumab facial redness: a multi-institution retrospective medical record review. J Am Acad Dermatol. 2020;82(1):230\u20132. https:\/\/doi.org\/10.1016\/j.jaad.2019.06.026.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"311_CR13","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1001\/jamadermatol.2019.2613","volume":"155","author":"A Soria","year":"2019","unstructured":"Soria A, Du-Thanh A, Seneschal J, Jachiet M, Staumont-Sall\u00e9 D, Barbarot S. Development or exacerbation of head and neck dermatitis in patients treated for atopic dermatitis with dupilumab. JAMA Dermatol. 2019;155(11):1312\u20135. https:\/\/doi.org\/10.1001\/jamadermatol.2019.2613.","journal-title":"JAMA Dermatol"},{"issue":"10","key":"311_CR14","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.jdcr.2019.07.020","volume":"5","author":"FSA de Beer","year":"2019","unstructured":"de Beer FSA, Bakker DS, Haeck I, et al. Dupilumab facial redness: positive effect of itraconazole. JAAD Case Rep. 2019;5(10):888\u201391. https:\/\/doi.org\/10.1016\/j.jdcr.2019.07.020.","journal-title":"JAAD Case Rep"},{"key":"311_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16218","author":"N Belhomme","year":"2020","unstructured":"Belhomme N, Gaignon T, Jouneau S, et al. Drug-induced granulomatosis: is dupilumab the new kid on the block? J Eur Acad Dermatol Venereol. 2020. https:\/\/doi.org\/10.1111\/jdv.16218.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"311_CR16","unstructured":"US FDA. Trogarzo\u2122 (ibalizumab-uiyk) injection [prescribing information]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761065lbl.pdf. Accessed 22 Dec 2019."},{"key":"311_CR17","unstructured":"US FDA. Sylvant (siltuximab) [prescribing information]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/125496s000lbl.pdf. Accessed 23 Dec 2019."},{"issue":"30","key":"311_CR18","doi-asserted-by":"publisher","first-page":"30408","DOI":"10.18632\/oncotarget.4655","volume":"6","author":"F van Rhee","year":"2015","unstructured":"van Rhee F, Casper C, Voorhees PM, et al. A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease. Oncotarget. 2015;6(30):30408\u2013199.","journal-title":"Oncotarget"},{"key":"311_CR19","unstructured":"CDC. Chagas disease: what US clinicians need to know. https:\/\/www.cdc.gov\/parasites\/cme\/chagas\/lesson_3\/20.html. Accessed 12 May 2020."},{"key":"311_CR20","unstructured":"Infectious Disease Advisor. CDC advises that benznidazole now only available through drug company. Published 27 August, 2018. Available from: https:\/\/www.infectiousdiseaseadvisor.com\/home\/topics\/vector-borne-illnesses\/cdc-advises-that-benznidazole-now-only-available-through-drug-company\/. Accessed 12 May 2020."},{"key":"311_CR21","unstructured":"US FDA. Benznidazole tablets, for oral use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209570lbl.pdf. Accessed 31 Dec 2019."},{"issue":"2","key":"311_CR22","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1590\/s0037-86822010000200015","volume":"43","author":"VMO de Pontes","year":"2010","unstructured":"de Pontes VMO, de Souza J\u00fanior AS, da Cruz FMT, et al. Adverse reactions in Chagas disease patients treated with benznidazole, in the State of Cear\u00e1 [in Portuguese]. Rev Soc Bras Med Trop. 2010;43(2):182\u20137. https:\/\/doi.org\/10.1590\/s0037-86822010000200015.","journal-title":"Rev Soc Bras Med Trop"},{"key":"311_CR23","unstructured":"ScienceDirect. Acute generalized exanthematous pustulosis due to benznidazole. https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S2213219814003833?via%3Dihub. Accessed 10 Jan 2020."},{"issue":"3","key":"311_CR24","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1111\/bjd.14451","volume":"175","author":"J Gonz\u00e1lez-Ramos","year":"2016","unstructured":"Gonz\u00e1lez-Ramos J, Noguera-Morel L, Tong HY, et al. Two cases of overlap severe cutaneous adverse reactions to benznidazole treatment for asymptomatic Chagas disease in a nonendemic country. Br J Dermatol. 2016;175(3):604\u20137. https:\/\/doi.org\/10.1111\/bjd.14451.","journal-title":"Br J Dermatol"},{"issue":"3","key":"311_CR25","first-page":"123","volume":"24","author":"B Carrilero","year":"2011","unstructured":"Carrilero B, Murcia L, Martinez-Lage L, Segovia M. Side effects of benznidazole treatment in a cohort of patients with Chagas disease in non-endemic country. Rev Esp Quimioter. 2011;24(3):123\u20136.","journal-title":"Rev Esp Quimioter"},{"issue":"3","key":"311_CR26","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.jaip.2016.09.047","volume":"5","author":"B Noguerado-Mellado","year":"2017","unstructured":"Noguerado-Mellado B, Rojas-P\u00e9rez-Ezquerra P, Calder\u00f3n-Moreno M, Morales-Cabeza C, Tornero-Molina P. Allergy to benznidazole: cross-reactivity with other nitroimidazoles. J Allergy Clin Immunol Pract. 2017;5(3):827\u20138. https:\/\/doi.org\/10.1016\/j.jaip.2016.09.047.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"11","key":"311_CR27","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1093\/cid\/civ690","volume":"61","author":"F Salvador","year":"2015","unstructured":"Salvador F, S\u00e1nchez-Montalv\u00e1 A, Mart\u00ednez-Gallo M, et al. Evaluation of cytokine profile and HLA association in benznidazole related cutaneous reactions in patients with Chagas disease. Clin Infect Dis. 2015;61(11):1688\u201394. https:\/\/doi.org\/10.1093\/cid\/civ690.","journal-title":"Clin Infect Dis"},{"key":"311_CR28","unstructured":"US FDA. Epidiolex\u00ae (cannabidiol) oral solution [prescribing information]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210365lbl.pdf. Accessed 27 Dec 2019."},{"issue":"6","key":"311_CR29","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/DER.0000000000000422","volume":"29","author":"C Pettit","year":"2018","unstructured":"Pettit C, Massick S, Bechtel M. Cannabidiol-induced acute generalized exanthematous pustulosis. Dermatitis. 2018;29(6):345\u20136. https:\/\/doi.org\/10.1097\/DER.0000000000000422.","journal-title":"Dermatitis"},{"issue":"1","key":"311_CR30","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s40265-017-0854-6","volume":"78","author":"HA Blair","year":"2018","unstructured":"Blair HA. Dimethyl fumarate: a review in moderate to severe plaque psoriasis. Drugs. 2018;78(1):123\u201330. https:\/\/doi.org\/10.1007\/s40265-017-0854-6.","journal-title":"Drugs"},{"key":"311_CR31","unstructured":"EMC. Skilarence 120 mg gastro-resistant tablets: summary of product characteristics (SmPC). https:\/\/www.medicines.org.uk\/emc\/product\/7480\/smpc. Accessed 12 May 2020."},{"key":"311_CR32","unstructured":"US FDA. Tecfidera\u00ae (dimethyl fumarate) delayed-release capsules, for oral use [prescribing information]. https:\/\/www.tecfidera.com\/content\/dam\/commercial\/tecfidera\/pat\/en_us\/pdf\/full-prescribing-info.pdf. Accessed 31 Dec 2019."},{"issue":"10","key":"311_CR33","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1007\/s12325-018-0788-8","volume":"35","author":"H Ochi","year":"2018","unstructured":"Ochi H, Niino M, Onizuka Y, et al. 72-week safety and tolerability of dimethyl fumarate in Japanese patients with relapsing-remitting multiple sclerosis: analysis of the randomised, double blind, placebo-controlled, phase III APEX study and its open-label extension. Adv Ther. 2018;35(10):1598\u2013611. https:\/\/doi.org\/10.1007\/s12325-018-0788-8.","journal-title":"Adv Ther"},{"key":"311_CR34","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.msard.2018.12.032","volume":"28","author":"H Algahtani","year":"2019","unstructured":"Algahtani H, Shirah B, Marghalani S, Algarni A. Erythema nodosum in a patient with multiple sclerosis on dimethyl fumarate. Mult Scler Relat Disord. 2019;28:155\u20138. https:\/\/doi.org\/10.1016\/j.msard.2018.12.032.","journal-title":"Mult Scler Relat Disord"},{"key":"311_CR35","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.pediatrneurol.2016.01.010","volume":"57","author":"N Makhani","year":"2016","unstructured":"Makhani N, Schreiner T. Oral dimethyl fumarate in children with multiple sclerosis: a dual-center study. Pediatr Neurol. 2016;57:101\u20134. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2016.01.010.","journal-title":"Pediatr Neurol"},{"issue":"3","key":"311_CR36","doi-asserted-by":"publisher","first-page":"241","DOI":"10.2176\/nmc.ra.2014-0219","volume":"55","author":"Y Miyahi","year":"2015","unstructured":"Miyahi Y, Yoshimura S, Sakai N, et al. Effect of edaravone on favorable outcome in patients with acute cerebral large vessel occlusion: subanalysis of RESCUE-Japan Registry. Neurol Med Chir (Tokyo). 2015;55(3):241\u20137. https:\/\/doi.org\/10.2176\/nmc.ra.2014-0219.","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"311_CR37","unstructured":"US FDA. Radicava (edaravone injection), for intravenous use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209176lbl.pdf. Accessed 31 Dec 2019."},{"key":"311_CR38","unstructured":"US FDA. Omegaven (fish oil triglycerides) injectable emulsion [prescribing information]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/0210589s000lbledt.pdf. Accessed 27 Dec 2019."},{"key":"311_CR39","unstructured":"US FDA. Tavalisse\u2122 (fostamatinib disodium hexahydrate) tablets, for oral use [prescribing information]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/209299lbl.pdf. Accessed 23 Dec 2019."},{"key":"311_CR40","unstructured":"US FDA. Cresemba (isavuconazonium sulfate) [prescribing information]. https:\/\/www.astellas.us\/docs\/cresemba.pdf. Accessed 31 Dec 2019."},{"key":"311_CR41","unstructured":"US FDA. Press announcements. FDA approves Kalydeco to treat rare form of cystic fibrosis. https:\/\/web.archive.org\/web\/20160318062836\/https:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm289633.htm. Accessed 12 May 2020."},{"key":"311_CR42","unstructured":"US FDA. Orkambi\u00ae (lumacaftor\/ivacaftor) tablets, for oral use Orkambi\u00ae (lumacaftor\/ivacaftor) oral granules [prescribing information]. Available from: https:\/\/pi.vrtx.com\/files\/uspi_lumacaftor_ivacaftor.pdf. Accessed 31 Dec 2019."},{"issue":"7","key":"311_CR43","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1164\/rccm.201608-1754OC","volume":"195","author":"CE Milla","year":"2017","unstructured":"Milla CE, Ratjen F, Marigowda G, et al. Lumacaftor\/ivacaftor in patients aged 6\u201311 years with cystic fibrosis and homozygous for F508del-CFTR. Am J Respir Crit Care Med. 2017;195(7):912\u201320. https:\/\/doi.org\/10.1164\/rccm.201608-1754OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"311_CR44","unstructured":"US FDA. Moxidectin [prescribing information]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210867lbl.pdf. Accessed 23 Dec 2019."},{"issue":"6","key":"311_CR45","doi-asserted-by":"publisher","first-page":"e2953","DOI":"10.1371\/journal.pntd.0002953","volume":"8","author":"K Awadzi","year":"2014","unstructured":"Awadzi K, Opoku NO, Attah SK, Lazdins-Helds J, Kuesel AC. A randomized, single-ascending-dose, ivermectin-controlled, double-blind study of moxidectin in Onchocerca volvulus infection. PLoS Negl Trop Dis. 2014;8(6):e2953. https:\/\/doi.org\/10.1371\/journal.pntd.0002953.","journal-title":"PLoS Negl Trop Dis"},{"key":"311_CR46","unstructured":"US FDA. Ocaliva (obeticholic acid) tablets, for oral use [prescribing information]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/207999s000lbl.pdf. Accessed 31 Dec 2019."},{"key":"311_CR47","unstructured":"US FDA. Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) [prescribing information]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/206619lbl.pdf. Accessed 31 Dec 2019."},{"issue":"4","key":"311_CR48","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/ijd.13882","volume":"57","author":"FJ Navarro-Trivi\u00f1o","year":"2018","unstructured":"Navarro-Trivi\u00f1o FJ, Mu\u00f1oz-Medina L, Navarro-Navarro I, Ruiz-Villaverde R. Cutaneous eruptions by new therapies against hepatitis C virus infection: not as common as we presumed. Int J Dermatol. 2018;57(4):493\u20134. https:\/\/doi.org\/10.1111\/ijd.13882.","journal-title":"Int J Dermatol"},{"key":"311_CR49","unstructured":"Genentech. Esbriet\u00ae (pirfenidone): information for patients. https:\/\/www.gene.com\/patients\/medicines\/esbriet. Accessed 12 May 2020."},{"key":"311_CR50","unstructured":"Genentech. Esbriet\u00ae (pirfenidone) capsules and film-coated tablets, for oral use [prescribing information]. https:\/\/www.gene.com\/download\/pdf\/esbriet_prescribing.pdf. Accessed 31 Dec 2019."},{"key":"311_CR51","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.pdpdt.2018.11.015","volume":"25","author":"B Ferrer Guill\u00e9n","year":"2019","unstructured":"Ferrer Guill\u00e9n B, Gi\u00e1caman MM, Valenzuela O\u00f1ate C, Magdaleno Tapial J, Hern\u00e1ndez Bel P, P\u00e9rez FA. Pirfenidone-induced photosensitivity confirmed by pathological phototest. Photodiagn Photodyn Ther. 2019;25:103\u20135. https:\/\/doi.org\/10.1016\/j.pdpdt.2018.11.015.","journal-title":"Photodiagn Photodyn Ther"},{"key":"311_CR52","unstructured":"US FDA. Uptravi\u00ae (selexipag) tablets, for oral use [prescribing information]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/207947s000lbl.pdf. Accessed 31 Dec 2019."},{"key":"311_CR53","unstructured":"US FDA. Olysio (simeprevir) capsules, for oral use [prescribing information]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/205123s012lbl.pdf. Accessed 31 Dec 2019."},{"issue":"5","key":"311_CR54","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1111\/bcp.13221","volume":"83","author":"F Borgia","year":"2017","unstructured":"Borgia F, Cacciola I, Filomia R, Vaccaro M, Squadrito G, Cannav\u00f2 SP. Mucocutaneous toxicity during simeprevir treatment for hepatitis C: a single institution, retrospective case series. Br J Clin Pharmacol. 2017;83(5):1152\u20134. https:\/\/doi.org\/10.1111\/bcp.13221.","journal-title":"Br J Clin Pharmacol"},{"key":"311_CR55","unstructured":"US FDA. Sovaldi\u00ae (sofosbuvir) tablets, for oral use [prescribing information]. https:\/\/www.gilead.com\/~\/media\/Files\/pdfs\/medicines\/liver-disease\/sovaldi\/sovaldi_pi.pdf. Accessed 31 Dec 2019."},{"issue":"1","key":"311_CR56","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/hep4.1126","volume":"2","author":"N Verma","year":"2018","unstructured":"Verma N, Singh S, Sawatkar G, Singh V. Sofosbuvir induced Steven Johnson syndrome in a patient with hepatitis C virus-related cirrhosis. Hepatol Commun. 2018;2(1):16\u201320. https:\/\/doi.org\/10.1002\/hep4.1126.","journal-title":"Hepatol Commun"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-020-00311-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-020-00311-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-020-00311-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T23:19:52Z","timestamp":1623885592000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-020-00311-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,17]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["311"],"URL":"https:\/\/doi.org\/10.1007\/s40268-020-00311-6","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,17]]},"assertion":[{"value":"17 June 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No funding was received for the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Benjamin H. Kaffenberger is an investigator and funded by the Dermatology Foundation in the investigation of drug eruptions. Paul C. Macklis, Brittany Dulmage, Brady Evans, Misha Rosenbach, and Johann E. Gudjonsson have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}